Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum...

3
Study Design UIHC HIV Clinic Patients Invitation – Informed Consent eparinized Blood/Serum Obtained CD4, HIV VL measured Serum => GBV-C VL Cells => flow cytometry s GBV-C alter B cell & NK cell activat r alter monocyte CCR5/CXCR4 expression C blunts T cell activation & prolifera C induces chemokines C CCR5 and CXCR4 on CD4 cells C replicates in T and B cells C D 4 C ounts ART G B- ART G + H + G B- H + G B+ 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 C D 4 count P=0.01 N=11 N=13 N=11 N=9 HIV VL G B - G B + 0 100000 200000 300000 400000 500000 600000 H IV VL ns

Transcript of Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum...

Page 1: Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum Obtained CD4, HIV VL measured Serum => GBV-C VL Cells => flow.

Study Design

UIHC HIV Clinic PatientsInvitation – Informed Consent

Heparinized Blood/Serum Obtained

CD4, HIV VL measuredSerum => GBV-C VL

Cells => flow cytometry

Does GBV-C alter B cell & NK cell activationor alter monocyte CCR5/CXCR4 expression?

GBV-C blunts T cell activation & proliferationGBV-C induces chemokinesGBV-C CCR5 and CXCR4 on CD4 cellsGBV-C replicates in T and B cells

CD4 Counts

ART GB- ART G+ H+ GB- H+ GB+0

100200300400500600700800900

1000110012001300

CD

4 c

ou

nt

P=0.01

N=11 N=13 N=11 N=9

HIV VL

GB - GB +0

100000

200000

300000

400000

500000

600000H

IV V

Lns

Page 2: Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum Obtained CD4, HIV VL measured Serum => GBV-C VL Cells => flow.

CD19+ CD86+

ART GB- ART G+ H+ GB- H+ GB+0.0

2.5

5.0

7.5

10.0%

of

Cel

lsP=0.018

CD56brt CD16- / CD69+

ART GB- ART G+ H+ GB- H+ GB+0

5

10

15

20

25

% C

ell

s

P=0.009

B cell activation: GB+ < GB- p=0.024 HIV Viremic GB+ < GB- p=0.018

NK cell activation: CD56dim/CD16+: NS CD56brt/CD16-: If HIV RNA neg: NS If HIV RNA pos: GB+ < GB- p=0.009

Page 3: Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum Obtained CD4, HIV VL measured Serum => GBV-C VL Cells => flow.

CD14+/CCR5+

ART GB- ART G+ H+ GB- H+ GB+0

5

10

15

20

25

30

35

40

45

% C

ell

sMonocyte CCR5 expression GB+ < GB- p=0.009 HIV RNA+: GB+ < GB- p=0.03

CXCR4 GB+< GB-, but NS

CD14+/CXCR4+

ART GB- ART G+ H+ GB- H+ GB+40

50

60

70

80

90

100

% C

ell

s

P=0.03

Conclusion:GBV-C replication in vivo• Diminishes B cell activation• Blunts CD16+ NK cell activation• Downregulates monocyte CCR5

GBV-C replicates in T and B cells; however, replication limited to a very small percentage of cells.

Replication has not been shown in NK cells or monocytes. Effect in these cells may be due to induction of chemokines and/or cytokines

The effect of GBV-C activation on T and B lymphocytes, NK cells and monocytes may contribute to prolonged survival in HIV- infected individuals.


Selected National HIV Prevention and Care Outcomes...HIV Care Continuum Outcomes, by Sex, 2018—United States Note. Receipt of medical care was defined as ≥1 test (CD4 or VL) in

Selected National HIV Prevention and Care Outcomes...HIV Care Continuum Outcomes, by Sex, 2018—United States Note. Receipt of medical care was defined as ≥1 test (CD4 or VL) in

HIV-1 Western Blot Cambridge Biotech · The Cambridge Biotech HIV-1 Western Blot Kit, when used as directed in this insert, will detect antibodies to HIV-1 when present in human serum,

HIV-1 Western Blot Cambridge Biotech · The Cambridge Biotech HIV-1 Western Blot Kit, when used as directed in this insert, will detect antibodies to HIV-1 when present in human serum,

Simon Collins HIV i-Base why we need evidence and not just ......for HIV transmissions when VL is undetectable . S Collins, HIV i-Base UK CAB ACTIVIST TRAINING OCTOBER 2014 Thanks

Simon Collins HIV i-Base why we need evidence and not just ......for HIV transmissions when VL is undetectable . S Collins, HIV i-Base UK CAB ACTIVIST TRAINING OCTOBER 2014 Thanks

The Future of HIV Diagnostics: Market Trends for CD4 and VL Testing Decade of Diagnostics Satellite Kuala Lumpur July 2, 2013.

The Future of HIV Diagnostics: Market Trends for CD4 and VL Testing Decade of Diagnostics Satellite Kuala Lumpur July 2, 2013.

HIV-1 gp120-specific Antibody Dependent Cell-mediated ... · HIV-1+ Elite Controllers have higher serum and CVL ADCC antibodies against HIV-1 gp120 than HIV-1+ Progressors on HAART

HIV-1 gp120-specific Antibody Dependent Cell-mediated ... · HIV-1+ Elite Controllers have higher serum and CVL ADCC antibodies against HIV-1 gp120 than HIV-1+ Progressors on HAART

HIV: Approach to CNS Disease - AWACCawacc.org/pdf/2012/4_HIV_Approach_to_CNS_Disease_by_Tracey_A_Cho_MD.pdf · Case 60 year-old man diagnosed with HIV one month prior (CD4 60, VL

HIV: Approach to CNS Disease - AWACCawacc.org/pdf/2012/4_HIV_Approach_to_CNS_Disease_by_Tracey_A_Cho_MD.pdf · Case 60 year-old man diagnosed with HIV one month prior (CD4 60, VL

HIV serology Laboratory : Distribution : 4235 Page 1 of 10 ... · plasma (serum) donations. Specimens 4240, 4241, 4244 and 4245 consisted of HIV 1/2 Ag/Ab positive donations, diluted

HIV serology Laboratory : Distribution : 4235 Page 1 of 10 ... · plasma (serum) donations. Specimens 4240, 4241, 4244 and 4245 consisted of HIV 1/2 Ag/Ab positive donations, diluted

Laboratory Procedure Manual Procedure Manual . Analyte: HIV Antibody / HIV Western Blot Confirmatory Test . Matrix: Serum . Method: Bio-Rad Laboratories HIV-1/HIV-2 plus

Laboratory Procedure Manual Procedure Manual . Analyte: HIV Antibody / HIV Western Blot Confirmatory Test . Matrix: Serum . Method: Bio-Rad Laboratories HIV-1/HIV-2 plus

VL 2263 - Technop · VL 4100 pag. 17 VL 4101 pag. 18 VL 4102 pag. 19 VL 4103 pag. 20 VL 4104 pag. 21 VL 4105 pag. 22 VL 4106 pag. 67 VL 4107 pag. 68 VL 5063 pag. 93 VL 5064 pag. 94

VL 2263 - Technop · VL 4100 pag. 17 VL 4101 pag. 18 VL 4102 pag. 19 VL 4103 pag. 20 VL 4104 pag. 21 VL 4105 pag. 22 VL 4106 pag. 67 VL 4107 pag. 68 VL 5063 pag. 93 VL 5064 pag. 94

SVN511 CT MG-DHPL013EN EX1 · MG-DHPL013EN 1510ITP/ZZZ-EX1 Model Composition VL-SVN511EX VL-MVN511EX x 1, VL-V555EX x 1 VL-SVN511FX VL-MVN511FX x 1, VL-V555FX x 1 Screw x 2 Mounting

SVN511 CT MG-DHPL013EN EX1 · MG-DHPL013EN 1510ITP/ZZZ-EX1 Model Composition VL-SVN511EX VL-MVN511EX x 1, VL-V555EX x 1 VL-SVN511FX VL-MVN511FX x 1, VL-V555FX x 1 Screw x 2 Mounting

Models VL-200 & VL-300

Models VL-200 & VL-300

Global Prevalence of HBV, HCV , HIV - American College of ...s3.gi.org/acgmeetings/2016/pgsyllabus/2016PG_0037.pdf · HIV=human immunodeficiency virus; ... Serum samples from patients

Global Prevalence of HBV, HCV , HIV - American College of ...s3.gi.org/acgmeetings/2016/pgsyllabus/2016PG_0037.pdf · HIV=human immunodeficiency virus; ... Serum samples from patients

5 Wheels - RVUSA.com · model vl-240rl vl-250rl vl-270bh vl-280rl vl-290rl vl-295bh vl-310bh vl-360db vl-365md dry weight 6976 7782 7704 8366 8646 8572 8936 11276 11058 gvwr 9100

5 Wheels - RVUSA.com · model vl-240rl vl-250rl vl-270bh vl-280rl vl-290rl vl-295bh vl-310bh vl-360db vl-365md dry weight 6976 7782 7704 8366 8646 8572 8936 11276 11058 gvwr 9100

Laboratory Procedure Manual...Laboratory Procedure Manual Analyte: HIV Antibody / HIV Western Blot Confirmatory Test Matrix: Serum Method: Bio-Rad Laboratories HIV-1/HIV-2 plus O EIA

Laboratory Procedure Manual...Laboratory Procedure Manual Analyte: HIV Antibody / HIV Western Blot Confirmatory Test Matrix: Serum Method: Bio-Rad Laboratories HIV-1/HIV-2 plus O EIA

Serum IL-12p70 and TLR 7 gene expression in Egyptian ... · Serum IL-12p70 and TLR 7 gene expression in Egyptian patients ... Current guidelines for ... HBV and HIV were tested by

Serum IL-12p70 and TLR 7 gene expression in Egyptian ... · Serum IL-12p70 and TLR 7 gene expression in Egyptian patients ... Current guidelines for ... HBV and HIV were tested by

Hyponatremia - Kettering Health Network...•Hyponatremia may worsen serum Osm < urine Osm with .9% saline •Example: 30 M HIV+ with PCP pneumonia and SIADH Serum Na 122; urine Osm

Hyponatremia - Kettering Health Network...•Hyponatremia may worsen serum Osm < urine Osm with .9% saline •Example: 30 M HIV+ with PCP pneumonia and SIADH Serum Na 122; urine Osm

VL-Z800S-S ITALIANO VL-Z800S-S - SHARP

VL-Z800S-S ITALIANO VL-Z800S-S - SHARP

Purification of HIV RNA from Serum Using a Polymer Capture Matrix

Purification of HIV RNA from Serum Using a Polymer Capture Matrix

Technical Brief on HIV Viral Load Technologies (June...2010/09/30  · 4.5 VL testing and programme evaluation Through population level VL testing, HIV treatment programs can be evaluated.

Technical Brief on HIV Viral Load Technologies (June...2010/09/30  · 4.5 VL testing and programme evaluation Through population level VL testing, HIV treatment programs can be evaluated.

STATENS SERUM INSTITUT Antiretroviral therapy and development of resistant HIV Louise Bruun Jørgensen Department of Virology Statens Serum Institut.

STATENS SERUM INSTITUT Antiretroviral therapy and development of resistant HIV Louise Bruun Jørgensen Department of Virology Statens Serum Institut.